Back
Gastroenteropancreatic neuroendocrine tumours (GEP-NET) - Imaging and staging.
Journal article

Gastroenteropancreatic neuroendocrine tumours (GEP-NET) - Imaging and staging.

  • Baumann T Clinic of Radiology and Nuclear Medicine, University of Basel Hospital, Basel, Switzerland.
  • Rottenburger C Clinic of Radiology and Nuclear Medicine, University of Basel Hospital, Basel, Switzerland; Center of Neuroendocrine and Endocrine Tumors, University of Basel Hospital, Basel, Switzerland.
  • Nicolas G Clinic of Radiology and Nuclear Medicine, University of Basel Hospital, Basel, Switzerland; Neuroendocrine Tumour Unit, Royal Free Hospital, London, UK.
  • Wild D Clinic of Radiology and Nuclear Medicine, University of Basel Hospital, Basel, Switzerland; Center of Neuroendocrine and Endocrine Tumors, University of Basel Hospital, Basel, Switzerland. Electronic address: damian.wild@usb.ch.
Show more…
  • 2016-03-15
Published in:
  • Best practice & research. Clinical endocrinology & metabolism. - 2016
GEP NET
PET/CT
SRS
gastroenteropancreatic neuroendocrine tumour
glucagon-like peptide-1 receptor imaging
somatostatin receptor imaging
Humans
Intestinal Neoplasms
Magnetic Resonance Imaging
Neoplasm Staging
Neuroendocrine Tumors
Pancreatic Neoplasms
Positron Emission Tomography Computed Tomography
Radiopharmaceuticals
Stomach Neoplasms
English Detection of gastroenteropancreatic neuroendocrine tumours (GEP-NETs) and monitoring of treatment response relies mainly on morphological imaging such as computed tomography (CT) and magnetic resonance imaging (MRI). Molecular imaging techniques also in combination with CT (hybrid imaging) greatly benefit patient management, including better localization of occult tumours and better staging. Somatostatin receptor scintigraphy (SRS) and somatostatin receptor (SSTR) positron emission tomography (PET) play a central role in the diagnostic work-up of patients with well-differentiated GEP-NETs. SSTR PET/CT is superior to SRS and should be used whenever available. (18)F-DOPA and (18)F-FDG PET/CT is inferior to SSTR PET/CT at least in patients with well-differentiated GEP-NETs. Both SSTR PET/CT and SRS have limitations, such as relatively low detection rate of benign insulinomas, poorly differentiated GEP-NETs and liver metastases. New innovations such as SSTR PET/MRI, radiolabelled SSTR antagonists and glucagon-like peptide-1 receptor (GLP-1R) agonists might further improve imaging of GEP-NETs.
Language
  • English
Open access status
closed
Identifiers
Persistent URL
https://folia.unifr.ch/global/documents/246914
Statistics
Document views: 8 File downloads: